Lycia Therapeutics, Inc.

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. The company leverages its proprietary LYTAC platform to develop a pipeline of therapeutic candidates aimed at providing deep and durable elimination of extracellular proteins inadequately addressed by current therapies.